RGD Reference Report - [Effect of diethyldithiocarbamate on interleukin 2 production of patients with oral lichen planus and its clinical therapeutic efficacy]. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

[Effect of diethyldithiocarbamate on interleukin 2 production of patients with oral lichen planus and its clinical therapeutic efficacy].

Authors: Su, M  Qian, D H  Chen, Y H 
Citation: Su M, etal., Zhongguo Yao Li Xue Bao. 1991 Jul;12(4):378-80.
RGD ID: 8693327
Pubmed: PMID:1666936   (View Abstract at PubMed)

Diethyldithiocarbamate (DTC), a biological augmenting agent specific for T cells, was applied to treat patients with incipient oral lichen planus (OLP) who had been refractory to traditional therapy. DTC was administered orally (5 mg.kg-1, twice a week) for at least 3 months. Interleukin 2 (IL-2) production and lymphocyte proliferation of peripheral blood mononuclear cells (PBMC) were measured before and after the treatment. The bioactivity of IL-2 was determined by the use of IL-2 dependent cell line CTLL-2 and human recombinant IL-2. The results indicated that both IL-2 production of PBMC and lymphocyte proliferation increased (P less than 0.01). Clinical symptoms were improved significantly. The effective rate in 30 patients was 86.7%. It is suggested that the mechanism involves that DTC improves the cellular immunity of the patients.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
Oral Lichen Planus  IDA 8693327 RGD 
Oral Lichen Planus  ISOIL2 (Homo sapiens)8693327; 8693327 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Il2  (interleukin 2)

Genes (Mus musculus)
Il2  (interleukin 2)

Genes (Homo sapiens)
IL2  (interleukin 2)


Additional Information